A single-center study from India sheds light on the safety and efficacy of biosimilar tenecteplase relative to the reference agent for patients with acute ischemic stroke.
An analysis of survey data from 500 patients with immune-mediated diseases, including rheumatoid arthritis, psoriasis, and IBD, suggests fewer than 1-in-4 patients were knowledgeable on the concept of biosimilars, but were open to learning more and considering use.